atezolizumab + carboplatin + pemetrexed

Atezolizumab + carboplatin + pemetrexed is a combination regimen used primarily as first-line treatment for advanced or metastatic non-squamous non-small cell lung cancer (NSCLC). Atezolizumab is a monoclonal antibody that targets programmed death-ligand 1 (PD-L1), blocking its interaction with PD-1 and B7.1 receptors, thereby enhancing T-cell mediated immune responses against tumor cells. Carboplatin is a platinum-based chemotherapy agent that causes DNA crosslinking and apoptosis in rapidly dividing cells. Pemetrexed is an antifolate chemotherapeutic that inhibits multiple folate-dependent enzymes involved in the synthesis of nucleotides, leading to inhibition of DNA and RNA synthesis in cancer cells. This combination leverages both immunotherapy (atezolizumab) and cytotoxic chemotherapy (carboplatin, pemetrexed) to improve outcomes in patients with advanced NSCLC.

Brand names

AlimtaTecentriq

Other names

carboplatin + pemetrexed + atezolizumab